The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Study Finds Tocilizumab Could Be Treatment Option for Takayasu Arteritis

Study Finds Tocilizumab Could Be Treatment Option for Takayasu Arteritis

August 17, 2018 • By Carina Stanton

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Ditty_about_summer / shutterstock.com

Ditty_about_summer / shutterstock.com

For patients with refractory Takayasu arteritis (TAK), glucocorticoids (GCs) are often provided as the initial therapy for treatment. However, GCs are often associated with adverse effects for long-term use; relapse also occurs frequently during GC tapering.1 TAK involves interleukin (IL) 6. Tocilizumab—a recombinant, humanized, anti-IL-6 receptor (IL-6R) monoclonal antibody—was first reported by Nishimoto et al. for the successful treatment of a patient with TAK.2 Previous research investigating tocilizumab for patients with refractory TAK, in case reports and observational studies, has also demonstrated clinical responses and a steroid-sparing effect.3

You Might Also Like
  • Fellow’s Forum Case Report: Takayasu’s Arteritis
  • Fellow’s Forum Case Report: Aneurysm in Takayasu’s Arteritis
  • Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept
Explore This Issue
August 2018
Also By This Author
  • Large-Vessel Involvement Is an Independent Risk Factor Predicting GCA Mortality

Findings from the TAKT study, a randomized, double-blind, placebo-controlled, phase 3 trial in Japan, is the first comparative study of its kind to investigate the efficacy and safety of tocilizumab in patients with TAK. This research provides new data suggesting “tocilizumab may possess consistent clinical benefits or steroid-sparing effects in patients with Takayasu arteritis,” according to Yoshiya Tanaka, MD, one of the TAKT study investigators. Dr. Tanaka is a rheumatologist in the First Department of Internal Medicine in the School of Medicine at the University of Occupational and Environmental Health in Kitakyushu, Japan.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Rheumatologists should consider prescribing tocilizumab for refractory patients with Takayasu arteritis,” says Yoshikazu Nakaoka, MD, PhD, TAKT study lead investigator and director of the Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute in Osaka, Japan.

A Treatment Option for TAK

The prevalence of TAK is around 2.6 cases per million in the U.S. and higher in Japan, with approximately 60 cases per million.4,5 Dr. Tanaka describes TAK as occurring more frequently in young females and characterized by aortitis affecting the aorta and its major branches, coronary arteries and pulmonary arteries. Manifestations of this inflammatory disease can include systemic symptoms, head and neck symptoms, upper limb problems, hypertension and body pain.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the TAKT study, 36 patients aged 12 years old and older, diagnosed with TAK based on the Japanese Guidelines for Management of Vasculitis Syndrome 2008 and who relapsed within 12 weeks prior despite receiving treatment with oral GC were enrolled as intent to treat (ITT) and safety patients to understand time to relapse of TAK (the primary endpoint of the study).6 Within the ITT and safety patient groups, 18 patients received tocilizumab subcutaneously (162 mg/week) and 18 received placebo through random assignment. Patients’ background oral GC dose was reduced by 10% per week from Week 4 to a minimum of 0.1 mg/kg/day, according to this formula: GC dose at Week n=0.9(N-3). Investigators identified the hazard ratio (HR) for time to relapse of TAK in the ITT population as 0.41 (95.41% CI 0.15 to 1.10; P=0.0596), indicating there was no significant difference between tocilizumab and placebo. Relapse occurred in eight tocilizumab-treated patients (44.4%) and 11 placebo-treated patients (61.1%). The median treatment durations were 19.00 weeks in the tocilizumab group and 12.86 weeks in the placebo group. Reported vascular signs and symptoms in tocilizumab-treated and placebo-treated patients were 87.5% and 81.8%, respectively.1

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: Actemra, Takayasu arteritis (TAK), tocilizumabIssue: August 2018

You Might Also Like:
  • Fellow’s Forum Case Report: Takayasu’s Arteritis
  • Fellow’s Forum Case Report: Aneurysm in Takayasu’s Arteritis
  • Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept
  • The Link Between Takayasu’s Arteritis & Increased Stroke Risk

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)